[Pathomorphologic changes in the brain during long-term combined administration of lysergamide (LSD-25) and haloperidol (experimental morphologic study) s].
D000818:Animals; D001927:Brain Diseases / Q000139:chemically induced* / Q000473:pathology; D002540:Cerebral Cortex / Q000378:metabolism / Q000473:pathology*; D004247:DNA / Q000378:metabolism; D006220:Haloperidol / Q000633:toxicity*; D006651:Histocytochemistry; D007031:Hypothalamus / Q000378:metabolism / Q000473:pathology; D008238:Lysergic Acid Diethylamide / Q000633:toxicity; D008297:Male; D012313:RNA / Q000378:metabolism; D051381:Rats; D013788:Thalamus / Q000378:metabolism / Q000473:pathology*
D012313:RNA; D008238:Lysergic Acid Diethylamide; D004247:DNA; D006220:Haloperidol
Patomorfologicheskie izmeneniia v golovnom mozgu pri dlitel'nom sochetannom vvedenii lizergmida (LSD-25) i galoperidola (eksperimental'no-morfologicheskie issledovaniia) 2.